Deal Details
Specifica Is Acquired by a Leading Global CRO
Summary
Specifica Inc. (“Specifica” or the “Company”) has been acquired by a leading global CRO. Terms of the transaction were not disclosed.
Baird served as the exclusive financial advisor to Specifica Inc. on this transaction.
About
Specifica is a rapidly growing antibody engineering and discovery services company specializing in the creation of exceptional antibody libraries, using next-generation sequencing for quality control at all steps of construction and validation. The Company’s patented Generation 3 Antibody Library Discovery Platform yields drug-like antibodies directly from selections, minimizing the need for downstream affinity and biophysical engineering. Specifica provides its partners with exclusive libraries, each created from a unique donor diversity set not used for any other library, ensuring that each Gen 3 library is one of a kind. In addition to in-house antibody library designs, Specifica also collaborates closely with partners to create custom libraries in which essential elements are optimized according to partner needs. The power of the Generation 3 Platform may be accessed by engaging Specifica to execute antibody discovery and optimization campaigns, or by full transfer of the platform technology. Additionally, Specifica recently introduced AbXtract™, a powerful suite of antibody informatics tools, through its software partner OpenEye. Specifica is headquartered in Santa Fe, New Mexico.CONTACT US TO LEARN MORE
- Date
- October 2022
- Company
- Specifica Inc.
- Transaction
- M&A - Sellside
- Sectors
- Healthcare
- Verticals
-
Pharmaceutical Services
- Target Geography
- North America
- Acquiror Geography
- North America
Share
